Market revenue in 2023 | USD 398.8 million |
Market revenue in 2030 | USD 1,085.1 million |
Growth rate | 15.4% (CAGR from 2023 to 2030) |
Largest segment | Phase ii |
Fastest growing segment | Phase III |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Phase I, Phase II, Phase III, Phase IV |
Key market players worldwide | IQVIA Holdings Inc, Icon PLC, Labcorp Holdings Inc, Charles River Laboratories International Inc, PAREXEL, Syneos Health, Medpace Holdings Inc, Thermo Fisher Scientific Inc, Veristat, Novotech |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy clinical trials market will help companies and investors design strategic landscapes.
Phase ii was the largest segment with a revenue share of 49.9% in 2023. Horizon Databook has segmented the Japan cell and gene therapy clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
In Japan, there is a huge percentage of population above 65 years of age. Hence, repairing damaged organ, replacing damaged organs with stem-cells, and developing better cost-efficient medicines are incorporated in their vision. Japan is an attractive market for outsourcing for developed nations such as the U.S. The regulatory process is also supportive of faster clinical trial approval.
For instance, cell and gene therapy clinical trials can be started once the probable benefits are demonstrated by carrying out relatively smaller number of cell and gene therapy clinical trials. In recent years, the number of clinical trials in the country have significantly reduced.
The decline in number of clinical trials is due to the introduction of Clinical Trial Act in 2018, which was passed to prevent misconduct in trials by imposing strict regulations. The reduction in global-scale clinical trials activity of the country is likely to affect the clinical trials support services market.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan cell and gene therapy clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into Japan cell and gene therapy clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account